Amgen and Wyeth have added a “black box” warning to the U.S. prescribing information (PI) of Enbrel. The warning relates to the risk of infections, including tuberculosis. The companies contend that this warning is similar to labeling for other medicines in the tumor necrosis factor (TNF) inhibitor class. Previously, Enbrel’s label included a bolded warning regarding the risk of infections and tuberculosis. This information is now in a boxed warning and includes additional l...